Updates in Risk Stratification in Myelodysplastic Syndromes : The Cancer Journal

Secondary Logo

Journal Logo

Review Articles

Updates in Risk Stratification in Myelodysplastic Syndromes

Aguirre, Luis E. MD; Sallman, David A. MD; Stone, Richard MD; Komrokji, Rami S. MD

Author Information
The Cancer Journal 29(3):p 138-142, 5/6 2023. | DOI: 10.1097/PPO.0000000000000654


Risk stratification plays an essential role in treatment planning in myelodysplastic syndromes. For decades, the International Prognostic Scoring System and its revised version have provided unified consensus for clinical trial enrollment and design. These models relied on laboratory and cytogenetic data to estimate prognosis and dictate treatment paradigms. Critical developments in DNA sequencing techniques in recent years, as well as our growing understanding of the clonal dynamics of myelodysplastic syndromes and the role that specific mutations have in shaping disease-specific phenotypes and treatment susceptibilities, have made it possible to identify molecular markers that carry critical diagnostic and therapeutic relevance and remained unaccounted for in the older models. The Molecular International Prognostic Scoring System is a novel risk stratification model that integrates clinical, cytogenetic, and molecular data to devise a more refined prognostic tool that builds on the accuracy of the traditional models.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid